Previous 10 | Next 10 |
Orphazyme (ORPH) -53% on FDA thumbs down for arimoclomol; cuts FY21 outlook.Athira Pharma (ATHA) -30% after the decision to place CEO on temporary leave.Capstone Green Energy (CGRN) -26% on $10M capital raiseCellect Biotechnology (APOP) -9%.Arrival (ARVL) -9...
Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...
coffeekai/iStock via Getty Images Athira Pharma (ATHA) has lost ~23.9% in the post-market after announcing that its Board has placed the company’s president and CEO Leen Kawas on temporary leave pending a review in connection with a doctoral research conducted by Dr. Kawas at the ...
BOTHELL, Wash., June 17, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira“), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Mark Litton, PhD, ...
The company's Bryostatin drug is likely to read out positive data in current phase 2, despite its checkered past. Its current market cap is extremely low compared to other companies in this space - suggesting significant upside. A Nasdaq up-listing provides a catalyst as volume is...
BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Rachel Lenington as Chief...
Photo by Bet_Noire/iStock via Getty Images The clinical biopharmaceutical company Athira Pharma ([[ATHA]] +16.5%) has reached the highest level since March after Jefferies predicted its shares to gain as much as 50% in the event of an FDA approval for Alzheimer's disease therapy aducanumab. T...
- Jefferies Healthcare Conference - Goldman Sachs 42 nd Annual Global Healthcare Conference BOTHELL, Wash., May 26, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (“ Athira ”), a late clinical-stage biopharmaceutical company focus...
Athira Pharma (ATHA): Q1 GAAP EPS of -$0.25 beats by $0.05.Cash, cash equivalents and marketable securities were $357.7 million as of March 31, 2021 compared to $268.2 million as of December 31, 2020.Press Release For further details see: Athira Pharma EPS beats by $0.05
-Phase 2 trial initiation for Parkinson’s disease dementia program and IND submission for neuropsychiatric program planned by end of 2021- -Hosted educational webinar on targeting HGF/MET featuring leading neurologist Marwan Sabbagh, M.D- - Raised $103.5M...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...